Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1532-5415.2009.02636.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Interventions Targeting Insulin Resistance in Patients with Type 1 Diabetes: A Narrative Review.
Medicina (Kaunas)
December 2024
Department of Diabetes, "Pius Brinzeu" Emergency Hospital, 300723 Timisoara, Romania.
Insulin resistance (IR) is the most important factor involved in the pathogenesis of type 2 diabetes but may also develop in type 1 diabetes (T1DM). Developing IR in patients with T1DM may generate a burden in achieving glycemic targets and may deteriorate the overall prognosis. This review aims to describe the pathogenesis of IR in T1DM, summarize the common associations of IR with other conditions in patients with T1DM, describe the consequences of developing IR in these patients, and present the interventions that target IR in people with T1DM.
View Article and Find Full Text PDFExploring the DPP IV inhibitory potential: molecular docking and dynamic simulations of pyridine-3-carboxylic acid and pyrrolidine-2-carboxylic acid analogs.
J Biomol Struct Dyn
December 2024
Department of Pharmaceutical Chemistry, Dr. D. Y. Patil Institute of Pharmaceutical Science and Research, affiliated to SPPU, Pune, India.
Diabetes mellitus remains a global challenge, with Type 2 Diabetes Mellitus (T2DM) prevalence increasing from 4% to 6.4% in the past 30 years. Presently oral hypoglycaemic agents like GLP-1 agonists, biguanides, sulphonylureas, glinides, and thiazolidinediones are employed in clinical practice.
View Article and Find Full Text PDFPioglitazone increases risk of ischemic heart disease in patients with type 2 diabetes receiving insulin.
J Diabetes Complications
December 2024
Division of Infection, Department of Medicine, Tri-Service General Hospital SongShan Branch, National Defense Medical Center, Taipei City 10581, Taiwan; Department of Health Promotion and Health Education, National Taiwan Normal University, Taipei 106, Taiwan. Electronic address:
Aim: Studies evaluating the cardiovascular safety of pioglitazone show inconsistent results and ischemic heart disease (IHD) risks associated with different anti-diabetic drugs added to metformin uncontrolled type 2 diabetes mellitus (T2DM) are not assessed. This study aimed to evaluate IHD risk associated with pioglitazone and/or insulin added to patients with metformin uncontrolled T2DM.
Methods: Data were extracted from the National Health Insurance Research Database of Taiwan.
Exploring cutting-edge approaches in diabetes care: from nanotechnology to personalized therapeutics.
Naunyn Schmiedebergs Arch Pharmacol
October 2024
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo, 11829, Egypt.
Diabetes mellitus (DM) is a persistent condition characterized by high levels of glucose in the blood due to irregularities in the secretion of insulin, its action, or both. The disease was believed to be incurable until insulin was extracted, refined, and produced for sale. In DM, insulin delivery devices and insulin analogs have improved glycemic management even further.
View Article and Find Full Text PDFRepurposing metabolic regulators: antidiabetic drugs as anticancer agents.
Mol Biomed
September 2024
CureScience, 5820 Oberlin Dr, Suite 202, San Diego, CA, 92121, USA.
Drug repurposing in cancer taps into the capabilities of existing drugs, initially designed for other ailments, as potential cancer treatments. It offers several advantages over traditional drug discovery, including reduced costs, reduced development timelines, and a lower risk of adverse effects. However, not all drug classes align seamlessly with a patient's condition or long-term usage.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!